Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2026 09:20 ET | Source: US Capital Global

Invest in the Future of Plasma Therapeutics: US Capital Global Securities Announces $20 Million Offering for Thplasma

San Francisco, California, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, the SEC-registered broker-dealer affiliate of the global financial group US Capital Global, is...
July 20, 2026 04:31 ET | Source: Research and Markets

Cancer Monoclonal Antibody Collaboration and Licensing Deals, 2016-2026 | Presents Detailed Analysis of Upfronts, Milestones, and Royalty Structures Across Relevant Deals

Dublin, July 20, 2026 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2026" has been added to ResearchAndMarkets.com's offering.This report provides a...
July 14, 2026 05:00 ET | Source: Hummingbird Bioscience

Hummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery Awards

From 647 nominations globally, Hummingbird Bioscience emerged as a winner, recognizing the company’s AI-first approach to drug discovery and development.
July 03, 2026 05:11 ET | Source: Research and Markets

Rituximab Market Growth Driven by Multi-Indication Use in Oncology and Autoimmune Diseases

Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "Rituximab Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Key Factors Driving Rituximab...
June 15, 2026 10:54 ET | Source: BCC Research LLC

AI-Driven Bispecific Antibody Development Attracts $1+ Billion in Pharma Investments Amid Clinical Risk Mitigation Focus

According to BCC Research, AI is shifting from an innovation differentiator to a strategic necessity for companies developing bispecific antibody therapies
June 15, 2026 07:25 ET | Source: Dyadic International, Inc.

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
June 11, 2026 10:37 ET | Source: Research and Markets

Antibody Partnering Surges into 2026: Q1 Deals Top $36 Billion as Bispecifics and Discovery Platforms Drive Competition

Dublin, June 11, 2026 (GLOBE NEWSWIRE) -- The "Antibody Collaboration and Licensing Deals 2019-2026" report has been added to ResearchAndMarkets.com's offering. Antibody therapeutics carried...
June 03, 2026 07:00 ET | Source: JJP Biologics

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LADData support the start of a Phase 1b clinical trial in rheumatoid...
June 03, 2026 01:00 ET | Source: JJP Biologics

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LADData support the start of a Phase 1b clinical trial in rheumatoid...
May 21, 2026 09:12 ET | Source: Research and Markets

Chronic Gout Market Research Report 2026-2036 - Late-stage Pipeline, Including SEL-212 and Dapansutrile Signals a New Wave of Therapies

Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Global Chronic Gout Market: Focus on Drug Class, Disease Type, Distribution Channel, Country, and Region - Analysis and Forecast, 2026-2036" report has...